The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 (HR 8179) was introduced Friday (September 4), directs the FDA to use its authority and resources to set a clear regulatory framework for hemp and hemp derived CBD and assure consumer protection.
The new letter to Schrader and Griffith is signed by the American Herbal Products Association (AHPA), Consumer Healthcare Products Association (CHPA), Council for Responsible Nutrition (CRN), Hemp Industries Association (HIA), Midwest Hemp Council, National Cannabis Industry Association, National Grocers Association, United Natural Products Alliance (UNPA), US Hemp Authority, US Hemp Building Association, US Hemp Growers Association (USHGA), US Hemp Roundtable, Virginia Hemp Coalition, Vote Hemp, We Are For Better Alternatives (WAFBA), and the Wisconsin Hemp Alliance.
“In passing the 2018 Farm Bill, Congress made clear its intent to support the production and sale of hemp and hemp derivatives such as CBD. Thousands of American farmers planted hemp in response, with CBD and extract varieties of hemp representing the overwhelming majority of all hemp acreage sown thus far in the U.S,” states the letter.
“However, public announcements by FDA stating that it is illegal to sell ingestible hemp-derived CBD products have hindered commercial progress for these farmers. While the agency has primarily taken action against companies that have made improper disease claims, and while FDA officials have announced that they are investigating a regulatory pathway for CBD products, CBD commerce and investment have been chilled due to the absence of federal regulation, impairing job creation and economic opportunity for farmers and small businesses.